Another mutation in a different gene is PIK3CA, which drives resistance to EGFR-TKIs by activating bypass AKT signaling; it is found in 4% of patients with lung cancers [41] and in 3.5% of EGFR mutant NSCLC [49]. This evidence concerns the gene EGFR and lung carcinoma.